PGE1 receptor Inhibitors
1 drugsAbout PGE1 receptor
The Prostaglandin E1 receptor mediates the effects of prostaglandin E1 (PGE1), a lipid involved in vasodilation, inflammation, and smooth muscle relaxation. As a key player in the prostaglandin signaling pathway, it regulates diverse physiological processes.
Targeting the PGE1 receptor offers therapeutic potential by modulating these processes. Currently, there is no genetic evidence directly linking the PGE1 receptor to specific diseases.
The PGE1 receptor is targeted by one FDA-approved drug, EDEX, a small molecule. ENDO OPERATIONS is the sole company with an approved drug for this target.
Top PGE1 receptor Drugs
ENDO OPERATIONS is the only company with an approved drug targeting the PGE1 receptor.
Low competition suggests a potential market entry opportunity, but also indicates higher risk.
PGE1 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PGE1 receptor, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches.
PGE1 receptor Clinical Trials 9 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PGE1 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 | 50% |
| Phase 2 | 4 | 1 | 3 | 0 | 25% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
| Phase 4 | 2 | 1 | 1 | 0 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved PGE1 receptor drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PGE1 receptor. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PGE1 receptor Drug Approval Timeline (1997 - 1997)
The first and only drug, EDEX, was approved in 1997.
The lack of recent approvals indicates potential saturation or challenges in developing new PGE1 receptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PGE1 receptor. A trial counts if an approved drug acting on PGE1 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.